BioNTech SE (BNTX) AI Stock Analysis

• Market Cap: $26.86B
• Dividend Yield: N/A
• Average Volume (3M): 648.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 7.04%
• EPS Growth: -25.24%
• Country: US
• Employees: 6,772
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 240,398,730
• 10 Day Avg. Volume: 671,795
• 30 Day Avg. Volume: 648,218
• PEG Ratio: 0.23
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 9.62
• P/FCF Ratio: -108.15
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 2.25
• Enterprise Value/Gross Profit: 2.73
• Enterprise Value/Ebitda: -68.81
• 1Y Price Target: $139.60
• Price Target Upside: 24.98% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $105.00 ▼(-6.00% Downside)

BioNTech's overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.

Positive Factors

Oncology Pipeline Progress

Advancements in the oncology pipeline, particularly with Pumitamig, position BioNTech for potential product launches, enhancing long-term growth prospects.

Strategic Partnerships

The partnership with Bristol-Myers Squibb strengthens BioNTech's oncology market position and provides significant financial benefits, supporting sustainable growth.

Strong Financial Position

A robust financial position with substantial cash reserves ensures BioNTech can fund its oncology transition and invest in long-term growth initiatives.

Negative Factors

Net Loss and Profitability Challenges

Ongoing net losses highlight profitability challenges, which could strain financial resources and impact long-term sustainability if not addressed.

Cash Flow Issues

Declining cash flow growth indicates potential liquidity constraints, which could limit BioNTech's ability to invest in R&D and operational expansion.

Regulatory Delays

Regulatory delays in product submissions can hinder BioNTech's ability to bring new treatments to market, affecting revenue and competitive positioning.

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE is a biotechnology company based in Germany that focuses on the development of personalized immunotherapies for cancer and other serious diseases. The company utilizes its proprietary mRNA technology platform to create innovative therapeutics and vaccines, including its widely known COVID-19 vaccine developed in partnership with Pfizer. BioNTech operates primarily in the biopharmaceutical sector, with a strong emphasis on personalized medicine and immune-oncology.

How the Company Makes Money

BioNTech generates revenue primarily through the commercialization of its products, particularly its COVID-19 vaccine, which has been a significant source of income due to global demand and government contracts. The company has established key partnerships, notably with Pfizer, which has enabled it to scale production and distribution effectively. In addition to vaccine sales, BioNTech is also involved in research collaborations and licensing agreements, allowing it to earn milestone payments and royalties from its developed therapies. The diversification of its product pipeline, including cancer therapies and other mRNA-based treatments, further contributes to its revenue stream by targeting various therapeutic areas and expanding its market reach.

BioNTech SE Financial Statement Overview

Summary

BioNTech SE is experiencing financial challenges with a net loss and negative profit margins, despite a strong gross profit margin. The balance sheet is robust with low leverage, but cash flow issues persist, impacting overall financial health.

Income Statement

BioNTech SE has experienced significant volatility in its income statement metrics. The company showed strong revenue growth in the past but has faced a decline in recent years. The TTM data indicates a slight revenue growth of 9.52%, but the company is currently operating at a net loss with a negative net profit margin of -12.07%. The gross profit margin remains strong at 79.76%, indicating efficient production, but negative EBIT and EBITDA margins suggest operational challenges.

Balance Sheet

The balance sheet of BioNTech SE is relatively strong, with a low debt-to-equity ratio of 0.0146, indicating minimal leverage and financial risk. However, the return on equity is negative at -1.83%, reflecting recent profitability challenges. The equity ratio is healthy, suggesting a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

BioNTech SE's cash flow statement reveals challenges, with a significant decline in free cash flow growth at -57.32% TTM. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. However, the free cash flow to net income ratio is positive at 1.48, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.15B	2.75B	3.82B	17.31B	18.98B	482.30M
Gross Profit	2.60B	2.21B	3.22B	14.32B	16.07B	423.00M
EBITDA	-103.30M	-367.10M	1.38B	13.10B	15.00B	-105.10M
Net Income	-571.60M	-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet
Total Assets	21.34B	22.53B	23.01B	23.28B	15.83B	2.32B
Cash, Cash Equivalents and Short-Term Investments	14.53B	16.78B	16.55B	14.06B	2.07B	1.35B
Total Debt	245.40M	254.20M	219.10M	212.20M	301.50M	240.10M
Total Liabilities	2.86B	3.12B	2.76B	3.22B	3.94B	946.80M
Stockholders Equity	18.48B	19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow
Free Cash Flow	-1.09B	-244.60M	4.67B	13.21B	735.70M	-98.90M
Operating Cash Flow	-316.80M	207.70M	5.37B	13.58B	889.70M	-13.50M
Investing Cash Flow	863.80M	-2.08B	-6.95B	-35.30M	-566.10M	-144.80M
Financing Cash Flow	-45.90M	-45.90M	-778.60M	-1.42B	94.20M	894.70M

BioNTech SE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 111.70
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 111.7 is above the 20-day moving average (MA) of 105.38, above the 50-day MA of 103.10, and above the 200-day MA of 105.28, indicating a neutral trend. The MACD of 0.73 indicates Negative momentum. The RSI at 47.90 is Neutral, neither overbought nor oversold. The STOCH value of 67.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.

BioNTech SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARGX	76 Outperform	$55.52B	41.80	24.75%	―	89.58%	―
GMAB	76 Outperform	$18.78B	12.83	28.20%	―	24.98%	127.06%
SWTX	61 Neutral	―	―	―	―	730.42%	31.63%
ALNY	57 Neutral	$59.81B	1,883.28	32.73%	―	53.24%	―
BNTX	53 Neutral	$26.86B	―	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRNA	50 Neutral	$9.67B	―	-29.32%	―	-56.00%	-38.95%

BioNTech SE Corporate Events

BioNTech Unveils Strategic Advances at R&D Day 2025

On November 11, 2025, BioNTech SE hosted its Innovation Series R&D Day, where it outlined its strategic direction and clinical advancements across its pipeline. The event highlighted BioNTech’s unique approach to innovation and its differentiated clinical strategy in oncology, including the development of mRNA cancer immunotherapies. The presentation emphasized the company’s ongoing efforts to establish Pumitamig1 in foundational tumor types and its partnership with Bristol Myers Squibb. This event reflects BioNTech’s commitment to advancing cancer treatment and its continued impact on the biotechnology industry.

BioNTech Reports Q3 2025 Financials and Raises Revenue Guidance

On November 3, 2025, BioNTech SE announced its third-quarter financial results, highlighting a revenue increase to €1.5 billion, despite a net loss of €28.7 million. The company reported progress in its oncology strategy, particularly with the bispecific antibody candidate pumitamig, and launched a variant-adapted COVID-19 vaccine for the 2025/2026 season. BioNTech also raised its full-year revenue guidance to €2.6-2.8 billion, supported by a $1.5 billion payment from its partnership with Bristol Myers Squibb.

BioNTech Reports Q3 2025 Financial Results with Revenue Growth Amid Operating Loss

On November 3, 2025, BioNTech SE announced its financial results for the three and nine months ending September 30, 2025. The company reported revenues of €1,518.9 million for the third quarter, reflecting a significant increase from the previous year. However, despite the revenue growth, BioNTech experienced an operating loss of €46.9 million for the quarter, attributed to increased research and development expenses and other operating costs. This financial update highlights the company’s ongoing investment in its pipeline and the challenges of balancing revenue growth with operational costs.

BioNTech Launches Exchange Offer for CureVac Shares to Boost Oncology Strategy

On October 22, 2025, BioNTech SE announced the commencement of a public exchange offer for all outstanding shares of CureVac N.V., as part of a strategic acquisition to enhance its capabilities in mRNA-based cancer immunotherapy. This acquisition is expected to strengthen BioNTech’s research, development, manufacturing, and commercialization efforts, marking a significant milestone in its oncology strategy. The transaction, valued at approximately $1.25 billion, aims to create long-term value for shareholders and advance the development of innovative cancer treatments.

BioNTech Hosts Second AI Day to Showcase AI Integration

On October 1, 2025, BioNTech SE, in collaboration with InstaDeep Ltd., hosted its second AI Day as part of its Innovation Series. The event highlighted BioNTech’s AI strategy and its application in the company’s pipeline and internal processes. This initiative underscores BioNTech’s commitment to leveraging AI to advance its position in the biotechnology industry, potentially impacting its operational efficiency and stakeholder engagement.

BioNTech and BMS Reveal Promising Phase 2 Results for Lung Cancer Treatment

On September 8, 2025, BioNTech SE and Bristol Myers Squibb presented interim data from a Phase 2 trial evaluating pumitamig, a bispecific antibody, in patients with extensive-stage small cell lung cancer. The data showed promising antitumor activity, with a 76.3% confirmed objective response rate and a 100% disease control rate, suggesting potential for pumitamig to become a new standard of care in this aggressive cancer type. The trial’s results are being used to inform a global Phase 3 trial, and pumitamig has received Orphan Drug designation from the FDA.

BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy

On June 2, 2025, BioNTech SE entered into a Global Co-Development and Co-Commercialization Agreement with Bristol-Myers Squibb Company to develop, manufacture, and commercialize the bispecific antibody BNT327 for various solid tumor types. The agreement, which was amended on August 15, 2025, includes a $1.5 billion upfront payment to BioNTech and up to $7.6 billion in additional milestone payments. The collaboration will see both companies sharing profits and losses equally, with a focus on maximizing the success and efficiency of BNT327’s development and commercialization. This strategic partnership is expected to enhance BioNTech’s position in the oncology market and provide significant financial benefits.

BioNTech and DualityBio’s Phase 3 Trial Success in Breast Cancer

On September 5, 2025, BioNTech SE and Duality Biologics announced that their Phase 3 trial in China for trastuzumab pamirtecan (BNT323/DB-1303) met its primary endpoint of progression-free survival in patients with HER2-positive metastatic breast cancer. This milestone marks the first positive Phase 3 data from their strategic collaboration, highlighting the potential of trastuzumab pamirtecan as a new treatment option. The success of this trial strengthens BioNTech’s position in oncology and supports further development of the drug in other regions, including the U.S. and EU.

FDA Approves BioNTech and Pfizer’s New COVID-19 Vaccine for High-Risk Groups

On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration approved their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for adults aged 65 and older, and individuals aged 5 through 64 with underlying conditions at high risk for severe COVID-19 outcomes. This approval is based on extensive clinical and real-world data demonstrating the vaccine’s safety and efficacy. The vaccine targets the SARS-CoV-2 sublineage LP.8.1, aligning with FDA guidance to address circulating strains. Shipping of the vaccine will commence immediately to ensure availability in pharmacies, hospitals, and clinics across the U.S., reinforcing BioNTech’s and Pfizer’s positions in the vaccine market and their commitment to addressing public health needs.